The CONFIRM trial, a North American-based phase 3 randomized, placebo-controlled trial (n=300) comparing terlipressin to placebo in patients with HRS-AKI-verified reversal of HRS was reported in 63 patients (32%) in the terlipressin group and 17 patients (17%) in the placebo group (P=0.006), supporting that terlipressin, when combined with albumin, is associated with a higher likelihood of reversal of HRS [14,36]. This evidence concerns the gene ALB and acute kidney injury.